| Company | Date | Position | Consensus ⓘ | Price Target ⓘ | 2-Yr Return |
|---|---|---|---|---|---|
|
AMWL
American Well
|
Jun 17, 2026 | BUY |
Hold
+64.5% avg upside
15 analysts
|
$9.00
6.70% Upside
|
· |
|
HNGE
Hinge Health, Inc. Class A
|
Jun 12, 2026 | BUY |
Strong Buy
+7.5% avg upside
17 analysts
|
$80.00
15.22% Upside
|
+2.6% |
|
DOCS
Doximity
|
Jun 10, 2026 | HOLD |
Buy
+61.4% avg upside
27 analysts
|
$18.00
11.95% Downside
|
+2.2% |
|
VEEV
Veeva Systems
|
Jun 10, 2026 | BUY |
Strong Buy
+54.2% avg upside
36 analysts
|
$320.00
108.75% Upside
|
-2.9% |
|
HQY
Healthequity
|
Jun 05, 2026 | BUY |
Strong Buy
+33.4% avg upside
20 analysts
|
$125.00
46.71% Upside
|
-3.4% |
|
GDRX
GoodRx Holdings
|
Jun 02, 2026 | BUY |
Buy
+387.3% avg upside
28 analysts
|
$3.50
31.67% Upside
|
-11.5% |
|
PHR
Phreesia
|
May 28, 2026 | HOLD |
Strong Buy
+82.2% avg upside
21 analysts
|
$9.00
4.11% Downside
|
· |
|
HCAT
Health Catalyst
|
May 11, 2026 | HOLD |
Buy
+215.1% avg upside
15 analysts
|
$1.00
42.63% Downside
|
-13.8% |
|
OMDA
Omada Health, Inc.
|
May 08, 2026 | HOLD |
Strong Buy
+32.0% avg upside
11 analysts
|
$18.00
2.14% Upside
|
+17.9% |
|
TDOC
Teladoc
|
Apr 30, 2026 | HOLD |
Buy
+257.8% avg upside
37 analysts
|
$6.00
25.66% Downside
|
+17.0% |
|
OMCL
Omnicell
|
Apr 29, 2026 | BUY |
Strong Buy
+36.0% avg upside
12 analysts
|
$55.00
40.82% Upside
|
+0.1% |
|
CTEV
Claritev
|
Mar 19, 2026 | HOLD |
Strong Buy
-1.9% avg upside
8 analysts
|
$22.00
25.12% Downside
|
+93.9% |
|
WAY
Waystar Holding Corp.
|
Feb 19, 2026 | BUY |
Strong Buy
+106.0% avg upside
29 analysts
|
$36.00
94.90% Upside
|
-28.6% |
|
OSPN
OneSpan
|
Oct 06, 2015 | BUY |
Strong Buy
+78.5% avg upside
10 analysts
|
$34.00
151.87% Upside
|
-34.9% |
Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.